The efficacy of immune checkpoint inhibitors in thoracic malignancies.
Journal
European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
08
12
2020
accepted:
18
02
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
25
11
2021
Statut:
epublish
Résumé
The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5 years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesothelioma (MPM) improving the overall survival compared with standard treatment. This phenomenon is of huge relevance as both SCLC and MPM were considered orphan diseases without any significant improvement in the therapeutic strategy in the first-line setting during the last 15 years. In this review, we aim to review the efficacy of ICI in thoracic malignancies either in monotherapy or in combination, according to predictive biomarkers, and to the US Food and Drug Administration and the European Medicines Agency approvals of treatment strategies. We address the efficacy of these agents, especially in NSCLC according to PD-L1 expression and histologic subtype.
Identifiants
pubmed: 34615702
pii: 30/162/200387
doi: 10.1183/16000617.0387-2020
pmc: PMC9489136
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: J. Remon reports other funding support from MSD, Boehringer Ingelheim, Pfizer, BMS, AstraZeneca and Roche, and personal fees and other funding support from OSE Immunotherapeutics, outside the submitted work. Conflict of interest: F. Facchinetti has nothing to disclose. Conflict of interest: B. Besse reports grants from Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgène, Eli-Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma, outside the submitted work.
Références
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Lancet Respir Med. 2019 Mar;7(3):260-270
pubmed: 30660511
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
J Clin Oncol. 2019 Aug 20;37(24):2162-2170
pubmed: 29906252
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
J Clin Oncol. 2021 Feb 20;39(6):619-630
pubmed: 33439693
J Thorac Oncol. 2018 May;13(5):636-648
pubmed: 29378266
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
J Thorac Oncol. 2020 Oct;15(10):1636-1646
pubmed: 32781263
Hum Pathol. 2018 Jan;71:1-7
pubmed: 28811252
J Clin Oncol. 2020 May 10;38(14):1580-1590
pubmed: 32078391
J Thorac Oncol. 2017 Jan;12(1):110-120
pubmed: 27639678
Lancet Oncol. 2019 Oct;20(10):1395-1408
pubmed: 31422028
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
J Thorac Oncol. 2020 Jun;15(6):914-947
pubmed: 32179179
Lancet Oncol. 2020 Sep;21(9):1213-1223
pubmed: 32888453
Clin Lung Cancer. 2019 Sep;20(5):e564-e575
pubmed: 31279641
J Thorac Oncol. 2020 Mar;15(3):426-435
pubmed: 31629915
Lancet Oncol. 2017 Sep;18(9):1261-1273
pubmed: 28729154
PLoS One. 2015 Mar 16;10(3):e0121071
pubmed: 25774992
J Thorac Oncol. 2015 Apr;10(4):565-76
pubmed: 25658628
Oncologist. 2020 Jun;25(6):515-522
pubmed: 32233048
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
J Clin Oncol. 1997 Aug;15(8):2866-72
pubmed: 9256130
Front Oncol. 2019 Apr 16;9:264
pubmed: 31058078
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
Ann Oncol. 2020 Dec;31(12):1734-1745
pubmed: 32976938
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Br J Cancer. 2017 Oct 24;117(9):1341-1348
pubmed: 28817839
Cancer Immunol Res. 2016 Dec;4(12):1038-1048
pubmed: 27856426
EBioMedicine. 2019 Oct;48:191-202
pubmed: 31648983
J Thorac Oncol. 2019 Jul;14(7):1286-1295
pubmed: 31078775
J Thorac Oncol. 2015 Mar;10(3):426-30
pubmed: 25384063
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
Oncoimmunology. 2019 Jul 13;8(9):e1638211
pubmed: 31428531
Lancet Oncol. 2017 May;18(5):587-598
pubmed: 28373007
Clin Lung Cancer. 2020 Sep;21(5):455-463.e4
pubmed: 32586767
Lancet Oncol. 2013 Oct;14(11):1104-1111
pubmed: 24035405
J Immunother Cancer. 2019 Mar 28;7(1):87
pubmed: 30922388
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Lancet Oncol. 2018 Mar;19(3):347-355
pubmed: 29395863
Ann Oncol. 2018 May 1;29(5):1258-1265
pubmed: 29514216
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Hum Pathol. 2016 Jun;52:9-18
pubmed: 26980049
PLoS One. 2017 Aug 3;12(8):e0182665
pubmed: 28771603
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
J Thorac Oncol. 2020 Sep;15(9):1449-1459
pubmed: 32389639
Genome Med. 2019 Feb 18;11(1):8
pubmed: 30777124
Lancet Respir Med. 2015 Apr;3(4):301-9
pubmed: 25819643
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
J Immunother Cancer. 2019 Mar 8;7(1):65
pubmed: 30850021
Mayo Clin Proc. 2010 Sep;85(9):838-54
pubmed: 20810794
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Pathol Oncol Res. 2020 Oct;26(4):2363-2370
pubmed: 32506394
Ann Oncol. 2015 Sep;26 Suppl 5:v40-55
pubmed: 26314779
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
pubmed: 32468956
Mod Pathol. 2017 Jun;30(6):826-833
pubmed: 28281549
Eur J Cancer. 2018 Sep;101:191-200
pubmed: 30077124
JAMA Oncol. 2020 May 1;6(5):661-674
pubmed: 32271377
Ann Oncol. 2019 Oct 1;30(10):1653-1659
pubmed: 31435660
J Thorac Oncol. 2015 Mar;10(3):500-8
pubmed: 25402569
Ann Oncol. 2013 Jan;24(1):75-83
pubmed: 22858559
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-13437
pubmed: 27834213
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
Clin Cancer Res. 2019 Sep 15;25(18):5485-5492
pubmed: 31164373
J Thorac Oncol. 2020 Oct;15(10):1657-1669
pubmed: 32599071
J Thorac Oncol. 2018 Oct;13(10):1569-1576
pubmed: 29908324
Lung Cancer. 2019 Apr;130:35-41
pubmed: 30885349
Cancer Res. 2015 Jan 15;75(2):264-9
pubmed: 25488749
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
J Thorac Oncol. 2019 May;14(5):903-913
pubmed: 30664989
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Transl Lung Cancer Res. 2020 Aug;9(4):1169-1179
pubmed: 32953495
Transl Lung Cancer Res. 2020 Jun;9(3):639-645
pubmed: 32676326
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Oncology. 2019;97(4):228-235
pubmed: 31216560
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Future Oncol. 2020 Aug;16(23):1677-1681
pubmed: 32407147
Ann Oncol. 2020 Jul;31(7):902-911
pubmed: 32320754
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Lung Cancer. 2017 Jun;108:115-120
pubmed: 28625622
J Thorac Oncol. 2017 May;12(5):850-859
pubmed: 28257959
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
JAMA Oncol. 2019 Mar 1;5(3):351-357
pubmed: 30605211
Eur J Cancer. 2019 May;113:78-86
pubmed: 30991261
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Semin Oncol. 2019 Aug - Oct;46(4-5):380-384
pubmed: 31735362
J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580
pubmed: 29951307
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Int J Oncol. 2019 Nov;55(5):1157-1164
pubmed: 31545419
Oncoimmunology. 2015 Mar 19;4(6):e1009285
pubmed: 26155428
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
J Thorac Oncol. 2019 Feb;14(2):237-244
pubmed: 30316010
Oncotarget. 2018 Jan 8;9(6):6993-7009
pubmed: 29467945
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157
pubmed: 31754795
J Thorac Oncol. 2020 Aug;15(8):1351-1360
pubmed: 32302702
Lancet Respir Med. 2018 Jun;6(6):451-460
pubmed: 29773326
Diagn Pathol. 2018 May 22;13(1):30
pubmed: 29789013